REPROCELL USA Inaugurates GMP Manufacturing Facility for Stem Cells
30 May 2024
REPROCELL is pleased to announce the offering of Master Cell Bank (MCB) manufacturing service for generation of Human Induced Pluripotent Cells (hiPSC) and Human Mesenchymal Stem Cells (hMSC) for human therapeutic applications. BELTSVILLE, ...
New from REPROCELL: GMP Grade Stem Cell Master Cell Bank Service Expansion
18 April 2024
REPROCELL is pleased to announce the offering of Master Cell Bank (MCB) manufacturing service for the generation of Human Induced Pluripotent Cells (hiPSC) in Beltsville for human therapeutic applications. REPROCELL has been producing clini...
Histocell obtains AEMPS authorisation and GMP certification for its new manufacturing plant for cell therapy and associated biological medicinal products in Larrabetzu
31 January 2024
REPROCELL's clinical stem cells manufacturing partner Histocell has obtained AEMPS authorisation and GMP certification for its new manufacturing plant, that is located in Larrabetzu, Spain. Histocell's manufacturing plant produces cell ther...
Cellcolabs announces partnership with REPROCELL: Global distributorship for research- and GMP-grade MSC and MSC derivatives
15 January 2024
SOLNA, Sweden and YOKOHAMA, Japan – Cellcolabs AB, a spin-out of the Karolinska Institute specialized in manufacturing both research- and GMP-grade mesenchymal stem cells (MSC), and REPROCELL Inc., Japan’s first induced pluripotent stem cel...
REPROCELL signs Strategic Collaboration Agreement with TEXCELL to boost its GMP iPSC - Master Cell Bank Manufacturing Service
02 September 2021
Yokohama Japan, 02 September 2021: REPROCELL have signed a Strategic Collaboration Agreement with TEXCELL JAPAN, a TEXCELL Group Company, for GMP iPSC - Master Cell Banks (MCB) Manufacturing. The TEXCELL Group (hereinafter “TEXCELL”) is a c...
REPROCELL's solution for GMP iPSC development - Seed iPSC Manufacturing Suite
29 June 2021
Maryland, USA: REPROCELL has opened a new Seed iPSC Manufacture Suite (SiMS) in response to increasing demand for iPSC-derived Master Cell Banks (MCBs). At this new US facility, REPROCELL will provide a comprehensive workflow of clinical st...
REPROCELL Launches cGMP suite in Kawasaki to Accelerate Development of iPSC-derived Glial Progenitors for treatment of CNS disorders
13 May 2019
Yokohama Japan – REPROCELL Inc. today announced that it has established the current good manufacturing practice (cGMP) cell processing suite at Life Innovation Center (LIC) in Tonomachi area in Kawasaki City for production of iPS Cell-deriv...